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A Summary of the Inaugural WHO
Classification of Pediatric Tumors:
Transitioning from the Optical into the
Molecular Era
Stefan M. Pfister1,2,3, Miguel Reyes-Múgica4,5, John K.C. Chan6, Henrik Hasle7, Alexander J. Lazar8,
Sabrina Rossi9, Andrea Ferrari10, Jason A. Jarzembowski11, Kathy Pritchard-Jones12, D. Ashley Hill13,
Thomas S. Jacques14,15, Pieter Wesseling16,17, Dolores H. López Terrada18, Andreas von Deimling19,20,
Christian P. Kratz21, Ian A. Cree22, and Rita Alaggio9

Pediatric tumors are uncommon, yet are the leading cause of cancer-related death
in childhood. Tumor types, molecular characteristics, and pathogenesis are unique,
often originating from a single genetic driver event. The specific diagnostic challenges of childhood
tumors led to the development of the first World Health Organization (WHO) Classification of Pediatric Tumors. The classification is rooted in a multilayered approach, incorporating morphology, IHC,
and molecular characteristics. The volume is organized according to organ sites and provides a single,
state-of-the-art compendium of pediatric tumor types. A special emphasis was placed on “blastomas,”
which variably recapitulate the morphologic maturation of organs from which they originate.

ABSTRACT

Significance: In this review, we briefly summarize the main features and updates of each chapter of the
inaugural WHO Classification of Pediatric Tumors, including its rapid transition from a mostly microscopic into a molecularly driven classification systematically taking recent discoveries in pediatric
tumor genomics into account.
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INTRODUCTION
Why Pediatric Tumors Need a Separate
Classification
Childhood tumors are fundamentally different in many
ways from those occurring in adults. Despite being extremely
heterogeneous, they account for only approximately one percent of all tumor diagnoses, but at the same time represent
the most common cause of disease-related death in children
(1). In contrast to malignancies in adults, which are mostly of
epithelial origin and often caused by an extended exposure
to carcinogens, tumors in childhood are often derived from
the mesoderm or neuroectoderm, and, with the exception
of hereditary cancer predisposition in approximately 10%
of patients, their etiology is largely unknown (2). According to data from the Leukemia and Lymphoma Society, the
most common groups of cancer in children, adolescents,
and young adults (CAYA; i.e., younger than 20 years) are:
leukemia (24.7%), tumors of the nervous system (17.2%), nonHodgkin lymphoma (7.5%), Hodgkin lymphoma (6.5%), and
soft-tissue sarcoma (5.9%). In contrast to cells successively
acquiring genetic hits over time in adults, pediatric tumors
are typically caused by a maturation block occurring in an
immature developing cell type (3). Tumors in children typically carry a much lower burden of genetic aberrations, often
driven by a single and thus clonal genetic driver event, such as
a translocation leading to an oncogenic fusion (4, 5). Tumors
in children predominantly show very limited immune cell
infiltration and are thus often considered immunologically
“cold” tumors (6–8). All of these unique properties of childhood cancers need to be considered when diagnosing and
ultimately treating these children, thus fully justifying a
separate World Health Organization (WHO) classification
specifically focusing on pediatric tumors. Given the relative
rarity of pediatric tumors compared with cancer in adults,
cooperation across multiple institutions, national and international consortia, are required to gather enough cases to
produce statistically significant data. However, these efforts
are complex and face many challenges, including difficulties in communication, sharing biological materials, diverse
classification systems applied in different regions of the
world, etc. With this in mind, this WHO pediatric tumor
classification represents a special effort to use a reproducible
and evidence-based taxonomic system, striving for a uniform
classification that may result in worldwide improvements.
This new WHO classification of pediatric tumors is
intended to support the pathologist responsible for diagnosing the tumor and the multidisciplinary team tailoring
treatment intensity to disease risk and matching patients to
specific therapies. It should also improve access to molecular genetic testing and, consequently, innovative treatments
for children with cancer through increased knowledge of
molecularly defined disease subtypes and therapeutic target
frequencies resulting from their routine assessment at the
time of diagnosis.

Tumor Classification According to WHO Criteria
For the first time, pediatric tumors are covered in a separate
volume in the new fifth edition of the WHO classification of
tumors. In previous editions, pediatric tumors were covered
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together with adult tumors in the respective organ systems.
As outlined before, it is increasingly clear that many aspects
of pediatric tumors differ significantly from those of adults.
Even tumors that histologically appear to be of the same type
often have distinctive etiology and pathogenesis, which is
reflected in their diagnosis and clinical behavior. In the fifth
edition series, this has been recognized and the opportunity
has been taken to describe these tumors in greater detail.
In keeping with other volumes in the fifth edition series,
the WHO Classification of Pediatric Tumors follows a hierarchical classification and lists tumors by site, category, family and type. Each tumor type is described with a common,
defined set of characteristics, and where information is not
available, this is clearly indicated. The classification is also
published on a website, which permits the use of whole-slide
images and hyperlinks to evidence cited. Improving the quality of evidence is an important facet of the evolution of the
classification of tumors, and hence diagnosis. As a result, we
have sought to include new information from methylation
studies, and other genomic investigations using HUGO Gene
Nomenclature Committee (HGNC) and Human Genome
Variation Society (HGVS) notation as appropriate. For those
tumors where assessment of proliferation is important for
diagnosis or prognosis, we recommend that mitoses are now
counted per millimeter squared, thus adhering to standardized international (SI) units, as microscope high-power fields
can be of variable size (9). We have also encouraged authors to
use medians rather than means when skewed data are being
considered. This is particularly important when pediatric age
distributions are considered.

Novel Diagnostic Technologies
The diagnostic shift from morphology to molecular
analyses is driven by both technology and the need for an
even more granular and unbiased classification to optimally
serve our patients. Foremost, the introduction of global
approaches including next-generation sequencing (NGS),
methylome analysis, and proteomics are driving this development. Tumor classification in recent years has been greatly
influenced by methylation analysis, being the technology
at present best suited for addressing lineage and thereby
the cell population of origin of tumors (10, 11). The stability of the diagnostic methylation pattern seen in multiple
specimens from the same tumor resection and throughout
further progression belies the concept of methylation states
representing cellular differentiation rather than neoplastic
changes (12). In contrast, NGS focuses on tumor-specific
alterations which may be pathognomonic in some instances,
especially in the context of genetically “simple” pediatric
tumors with gene fusions, focal amplifications, or point
mutations. NGS employed in common diagnostic settings
addresses differently sized gene panels (13) up to wholeexome (or even whole-genome) sequencing with a tendency
to shift toward the latter (14–18). The added value of integrating somatic and germline sequencing data is becoming
increasingly evident in this context. One diagnostically valuable NGS technology is RNA sequencing (RNA-seq), which
reliably detects pathognomonic gene fusions and provides
insight in the activity of gene transcription (19). Diagnostic protein analysis, currently almost exclusively facilitated
AACRJournals.org
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by IHC, will be supplemented by mass spectrometry–based
proteomics allowing simultaneous identification and quantification of several thousand proteins in tumor tissues (20,
21). There is an expectation that this will shed light on the
activity of cellular signaling pathways. For example, information about phosphoproteins could lead to recommendations
for specific inhibitory therapies. Proteome analyses may turn
out to be the most direct approach to tumor characterization,
as it combines the readout of cellular responses to epigenetic
differentiation settings, tumor-specific structural alterations,
and optimization-driven cellular regulation.
In conclusion, future tumor diagnostics are likely to rely
on several molecular platforms that contribute orthogonal
information to address the questions “where does it come
from?” (methylome analyses), “how far has it gone?” (NGS),
and “how to treat the patient?” (NGS, proteomics). That
said, morphologic tumor diagnostics is also progressing.
Identifying novel tumor types based on their molecular
profile is followed by focused histologic and IHC evaluation
that frequently detects diagnostic features, which can be
assessed with classic technologies. Examples are the primary
intracranial sarcoma, DICER1-mutant (22, 23), the diffuse
glioneuronal tumor with oligodendroglioma-like features
and nuclear clusters (24, 25), or the recently described
neuroepithelial tumor with PATZ1 fusion (26). Rapid progress is being made with artificial intelligence–based analysis of morphologic images, and this may contribute greatly
to tumor evaluation (27, 28). An important task to solve
is how to merge the different diagnostic molecular and
imaging platforms, including preoperative data, to make a
combined evaluation.

Integrated and Layered Diagnoses
A pathologic diagnosis serves the purpose of communicating information relevant for tailored management, including
on prognosis and therapeutic options, in the most condensed
manner. The diagnosis should be standardized and suitable
for local, national, and international communication. Among
several approaches, the WHO Classification system emerged
as most widely accepted. For a long time, the WHO Classification has provided recommendations on how to reach
diagnoses in ways which could be successfully performed in
most parts of the world. However, the enormous progress,
mainly in molecular diagnosis, which has far-reaching impact
on classification, grading, and therapy, is not compatible
anymore with such a highly condensed diagnosis or with
very different local requirements. When possible, a large
body of relevant information needs to be communicated,
but the amount of additional information gathered varies
from institution to institution and country to country. To
overcome this problem, a multilayered diagnosis resulting
in an integrated diagnosis has been devised (29, 30). Key to
this approach are four of the major characteristics consisting
of (i) a compilation of the data from ii–iv to an integrated
diagnosis, (ii) a (classic) morphologic evaluation, (iii) a tumor
grade, and (iv) a level providing the most salient molecular
information. The minimum requirements for reaching the
predefined integrated diagnoses are provided by the WHO
classification. While many tumors do fit such a matrix, two
problems may occur due to either a lack of information or
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nonmatching information. Where essential molecular tests
are not available, the solution is the addition of “not otherwise specified” (NOS) to the morphologic evaluation. In cases
where molecular information does not match a WHO tumor
type, the addition of “not elsewhere classified” (NEC) to the
diagnosis highlights this problem (30, 31). In summary, the
integrated diagnosis serves to communicate diagnoses based
on different levels of analyses while still maintaining a universal terminology.

ENTITY-SPECIFIC DEVELOPMENTS
Leukemias and Lymphomas
Hematolymphoid neoplasms are the most prevalent group
of cancers (38.7%) in CAYA. With increasing knowledge of
the genetics of hematolymphoid neoplasms, a molecularly
oriented classification has a significant impact on the accuracy of diagnosis, treatment, and prognosis. In recent years,
the availability of conjugated or unconjugated mAbs against
specific targets (such as CD20, CD19, CD22), small molecules
interfering with activated molecular pathways (such as tyrosine kinase inhibitors, γ-secretase inhibitors, FLT3 inhibitors),
and genetically engineered chimeric antigen receptor T cells
(CAR T) as immunotherapy has broadened the opportunities
to target the key genetic aberrations in patients with various
leukemias and lymphomas (32–36).
Hematopathology has been at the forefront in the adoption of newly available molecular techniques, and indeed the
current WHO classification of hematolymphoid neoplasms
has long since evolved from a morphologic classification to
a classification that integrates clinical, morphologic, immunophenotypical, and molecular features in the definition of
entities (37, 38).
The classification of hematolymphoid neoplasms in the
WHO Classification of Pediatric Tumors focuses on the landscape of these neoplasms in CAYA and is essentially an adaptation of the revised fourth edition of WHO Classification of
Tumors of Hematopoietic and Lymphoid Tissues (Table 1;
refs. 32, 39–41). Consequently, adult-type entities that are
rare or practically nonexistent in the CAYA age group, such
as chronic neutrophilic leukemia, polycythemia vera, essential thrombocythemia, chronic eosinophilic leukemia, and
chronic lymphocytic leukemia (CLL), are not part of the
pediatric classification, while they are described in detail in
the WHO Classification of Hematopoietic and Lymphoid
Tissues. Biological and genetic abnormalities are a defining
criterion in some entities, such as chronic myeloid leukemia
(CML), acute myeloid leukemia (AML) with recurrent genetic
abnormalities, large B-cell lymphoma with IRF4 rearrangement, and ALK-positive anaplastic large cell lymphoma. In
other entities, genetic aberrations contribute to the diagnosis,
identify prognostic categories, or represent targets potentially
amenable to therapy.
Leukemias and Myeloid Neoplasms

Leukemias comprise one fourth to one third of all malignancies in CAYA, with 80% being acute lymphoblastic leukemia (ALL), 15% AML, and 2% CML. Thus, the proportions of
the various leukemia types differ markedly from those seen in
adults (38% AML, 30% CLL, 15% CML, 11% ALL).
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Table 1. Classification of pediatric leukemias and lymphomas
Myeloid neoplasms
Myeloproliferative neoplasms
Chronic myeloid leukemia, BCR::ABL1 positive
Myelodysplastic/myeloproliferative neoplasms
Juvenile myelomonocytic leukemia
Myelodysplastic syndromes
Refractory cytopenia of childhood
Myelodysplastic syndrome with excess blasts
Myeloid neoplasms with germline predisposition
Myeloid proliferations associated with Down syndrome
Acute myeloid leukemia and related neoplasms
Acute myeloid leukemia, NOS
Acute myeloid leukemia with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1::RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11
APL with t(15;17)(q24.1;q21.2); PML::RARA
AML with KMT2A-rearrangement new
AML with t(6;9)(p23;q34.1); DEK::NUP214
AML with inv(3)(q21q26)/t(3;3)(q21;q26); GATA2, RPN1::MECOM
AML with ETV6-fusion new
AML with t(8;16)(p11.2;p13.3); KAT6A::CREBBP new
AML with t(1;22)(p13.3;q13.1); RBM15::MKL1
AML with CBFA2T3::GLIS2 (inv(16)(p13q24)) new
AML with NUP98-fusion new
AML with t(16;21)(p11;q22); FUS::ERG new
AML with mutated NPM1
AML with bZIP mutated CEBPA

Mast cell neoplasia
Mastocytosis

Lymphoid neoplasms
Precursor lymphoid neoplasms
B-cell lymphoblastic leukemia/lymphomas
B-LBLL with t(9;22)(q34.1;q11.2); BCR::ABL1
B-LBLL with t(v;11q23.3); KMT2A-rearranged
B-LBLL with t(12;21)(p13.2;q22.1); ETV6::RUNX1
B-LBLL with hypodiploidy, near- haploid
B-LBLL with hypodiploidy, low
B-LBLL with hypodiploidy, high
B-LBLL with t(5;14)(q31.1;q32.1); IGH::IL3
B-LBLL with t(1;19)(q23;p13.3); TCF3::PBX1
B-LBLL, BCR::ABL1-like (Philadelphia-like B-ALL)
B-LBLL with iAMP21
T-cell and natural killer (NK)-cell lymphoblastic leukemia/lymphoma
T-lymphoblastic leukemia/lymphoma
Early T-cell precursor lymphoblastic leukemia
NK-lymphoblastic leukemia/lymphoma
Mature B-cell neoplasms
Primary mediastinal (thymic) large B-cell lymphoma
Diffuse large B-cell lymphoma, NOS
EBV-positive diffuse large B-cell lymphoma, NOS
Large B-cell lymphoma with IRF4 rearrangement
Pediatric-type follicular lymphoma
Pediatric nodal marginal zone lymphoma
ALK-positive large B-cell lymphoma
Lymphomatoid granulomatosis
Plasmablastic lymphoma

OF4 | CANCER DISCOVERY

FEBRUARY 2022

AACRJournals.org

Downloaded from cancerdiscovery.aacrjournals.org on December 20, 2021. © 2021 American Association for
Cancer Research.

Published OnlineFirst December 17, 2021; DOI: 10.1158/2159-8290.CD-21-1094
Inaugural WHO Classification of Pediatric Tumors: A Summary

REVIEW

Table 1. Classification of pediatric leukemias and lymphomas (Continued)
Grey-zone lymphoma
Burkitt lymphoma
Burkitt-like lymphoma with 11q aberration
Mature T/NK-cell neoplasms
Peripheral T cell lymphoma
Aggressive NK-cell leukemia
Mycosis fungoides
Anaplastic large cell lymphoma, ALK-positive
Hepatosplenic T-cell lymphoma
Primary cutaneous CD30+ T-cell lymphoproliferative disorders
Systemic EBV+ T-cell lymphoma of childhood
Hydroa vacciniforme lymphoproliferative disorder
Subcutaneous panniculitis-like T-cell lymphoma

Hodgkin lymphoma

Classical Hodgkin lymphoma
Nodular lymphocyte predominant Hodgkin lymphoma

Histiocytic and dendritic cell neoplasms

Langerhans cell histiocytosis and other histiocytic/dendritic cell neoplasms

Immunodeficiency-associated lymphoproliferative disorders

Primary immunodeficiency associated lymphoproliferative disorders
Post-transplant lymphoproliferative disorders
HIV-associated lymphoproliferative disorders

NOTE: Changes respect to fourth edition of the WHO Classification are highlighted in red (new). Molecularly
defined entities are marked in green.

ALL represents the most common type of leukemia in
CAYA, with 85% being of B-lineage (B-ALL; B-lymphoblastic leukemia; ref. 42). Most cases show recurrent genetic
abnormalities (Table 1 and more detailed in Supplementary
Table S1), which have prognostic significance, for example,
B-ALL with ETV6::RUNX1, TCF3::PBX1 and high hyperdiploidy
is associated with a favorable outcome, whereas B-ALL with
hypodiploidy and KMT2A rearrangement is associated with a
poor prognosis (34). BCR::ABL-like (Philadelphia-like) B-ALL
is a high-risk B-ALL characterized by heterogeneous genetic
alterations, unified by a gene expression profile similar to Phpositive B-ALL while lacking BCR::ABL1 gene fusion (43).
Genetic alterations are variable and may include IKZF1 deletion, CRLF2 rearrangement and overexpression, JAK/IL7R
mutations, ABL1 class fusions, EPOR rearrangements, tyrosine
kinase pathway activation, and other less common genomic
alterations. As a result, for a precise diagnosis it is often necessary to apply multiple techniques such as gene expression profiling/RNA-seq, FISH, reverse transcription PCR, flow cytometry,
and NGS. The treatment of ALL has been a remarkable success
story in pediatric oncology, with a meager 5-year overall survival rate of 31% in 1975 that has improved to 90% nowadays
due to the adoption of risk-stratified dose-intensive chemotherapy (34). Disease-risk stratification can be improved further
by the incorporation of genomic data, which will also aid in
tailoring the treatment to minimize long-term side effects (35).
Childhood AML has an overall survival of about 70% despite
significant advances in risk classification, chemotherapy intensification, and stem cell transplantation (44, 45). Improved
understanding of the tumor biology and molecular pathways
of AML provides opportunities to design novel targeted

therapies, which will be facilitated by a classification with
emphasis on genetic aberrations (45). Subtypes of AML
with different recurrent genetic abnormalities are associated
with different prognoses (Table 1). Cases of AML that show
genetic changes not covered by the defined list can be classified
as AML, NOS, appended with the key molecular alterations.
The findings of the Children’s Oncology Group-National
Cancer Institute TARGET AML initiative on the molecular
landscape of pediatric AML, based on nearly 1,000 cases, are
particularly illuminating, highlighting differences from adult
AML (46). Some structural variants, such as new gene fusions
and focal deletions of MBNL1, SEB2, and ELF1, are much more
prevalent in pediatric compared with adult AML, while some
mutations common in adult AML (such as DNMT3A and
TP53) virtually never occur in pediatric AML (46). Some new
recurrent mutations (such as MYC-ITD, NRAS, KRAS) have
also been discovered (46). It is envisaged that the next edition
of the WHO Classification of Tumors of Haematopoietic and
Lymphoid Tissues will entail more pediatric-specific changes.
Among myeloid neoplasms, juvenile myelomonocytic leukemia (JMML), refractory cytopenia of childhood (RCC), and
myeloid proliferations associated with Down syndrome are
strictly pediatric diseases.
JMML is characterized by mutations in genes of the RAS
signaling pathway (47). PTPN11-, NRAS- or KRAS-mutated
JMML shows somatic gain-of-function mutations in nonsyndromic children, while NF1- or CBL-mutated JMML occurs
in type 1 neurofibromatosis and CBL mutation–associated
syndrome, respectively, characterized by germline mutation
and acquired biallelic inactivation of the respective tumor
suppressor genes.
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CANCER DISCOVERY | OF5

Downloaded from cancerdiscovery.aacrjournals.org on December 20, 2021. © 2021 American Association for
Cancer Research.

Published OnlineFirst December 17, 2021; DOI: 10.1158/2159-8290.CD-21-1094
Pfister et al.

REVIEW
RCC is distinct from adult myelodysplastic syndrome,
in that the bone marrow is often hypocellular, and somatic
alterations commonly seen in the latter, such as mutations
in TET2, DNMT3A, TP53, and the spliceosome complex, are
usually absent (48–50). In a proportion of cases, monosomy
7 is found (51–54), which was further shown to be associated
with germline mutations in GATA2 or SAMD9/9L (55).
Myeloid proliferations associated with Down syndrome
encompass transient abnormal myelopoiesis (TAM) and
myeloid leukemia of Down syndrome (ML-DS). TAM occurs
in newborns, and most cases show spontaneous remission,
although ML-DS may supervene in 1 to 3 years in some 25%
of cases. The disease is characterized by somatic mutations in
GATA1 ML-DS (56–58) and usually occurs before the age of 5
years. Most cases exhibit features of megakaryoblastic leukemia, and harbor GATA1 mutations plus additional mutations.
The spectrum of mutations is distinct from other pediatric and
adult AML, usually targeting genes encoding cohesin components, signal transducers, and epigenetic regulators (59, 60).
Lymphomas

A subset of pediatric lymphomas is associated with congenital immunodeficiencies or Epstein–Barr virus (EBV) infection,
but for the vast majority of children with lymphoma the etiology and predisposing factors are not known (40, 41). Pediatric
lymphomas show several features distinct from adult lymphomas. Most are precursor B-cell or T-cell lymphoblastic leukemias/lymphomas, high-grade B-cell lymphomas (particularly
Burkitt lymphoma) or, among mature T-cell lymphomas,
ALK-positive anaplastic large cell lymphomas (41, 61). Lowgrade B-cell lymphomas, such as CLL, follicular lymphoma,
lymphoplasmacytic lymphoma, and mantle cell lymphomas,
rarely occur in the pediatric age group. High-grade lymphomas (such as Burkitt lymphoma and diffuse large B-cell lymphoma) and Hodgkin lymphomas in the pediatric population
have an excellent prognosis (often curable in >90%), superior
to that observed in adults (62–64). Several lymphoma types
occur almost exclusively in the CAYA age group, including
pediatric-type follicular lymphoma, pediatric nodal marginal
zone lymphoma, large B-cell lymphoma with IRF4 rearrangement, systemic EBV+ T-cell lymphoma of childhood and
hydroa vacciniforme lymphoproliferative disorder.
Although the classification scheme of lymphomas is
less molecularly defined compared with the classification
of leukemias, most lymphoma types do exhibit distinctive
molecular alterations, some of which are defining, such as
ALK-positive anaplastic large cell lymphoma and large B-cell
lymphoma with IRF4 translocation (as indicated in Table 1).

Soft-Tissue and Bone Tumors
Classifications of soft-tissue and bone tumors have progressively integrated our increasing knowledge regarding
recurrent molecular alterations with the traditional diagnostic approach based on morphologic evidence of a lineage differentiation. A token of the limitations of classic morphology
for the classification of these tumors was the introduction of
a category for “unclassifiable sarcomas” in the 2013 fourth
edition of the WHO Classification of Soft Tissue and Bone
Tumors. In the current WHO 2020 fifth edition, this has
evolved into a growing group of newly characterized tumor
OF6 | CANCER DISCOVERY
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types that (at least so far) lack an identifiable lineage of
differentiation, but which are now defined by specific recurrent genetic/molecular alterations (ref. 65; Fig. 1A). By and
large, the WHO classification of pediatric tumors has been
built upon the backbone of the current WHO Classification
of Soft Tissue and Bone Tumors. It thoroughly describes
entities typical of pediatric age as well as the clinical, pathologic, and molecular features of adult-type tumors frequently
occurring in children, including particular pseudotumoral/
malformative lesions and hamartomas.
Benign Soft-Tissue Tumors

Benign soft-tissue tumors in children vastly outnumber
sarcomas, with benign myofibroblastic and vascular tumors
being the most frequently encountered lesions (66). Their
accurate characterization requires an expert integration of
clinical, histologic, and genetic/molecular findings to define
both their potential to progress and their possible role as a
sentinel event of more complex syndromes (66, 67). Compared with the 2020 WHO Classification of Soft Tissue and
Bone Tumors (65), a special emphasis has been placed on
benign vascular lesions, which have been redefined in light of
the clinical and pathogenetic orientation of the International
Society for the Study of Vascular Anomalies classification
(https://www.issva.org/classification). The term “hemangioma” has been dropped and replaced by capillary, venous
and arteriovenous malformations, intramuscular vascular
anomalies, and lymphatic anomalies, clearly defining their
malformative nature and the pathogenetic molecular pathways involved. Furthermore, complex malformations were
subdivided into different categories on the basis of molecular
alterations and associated syndromes (Table 2).
Soft-Tissue Sarcomas

Soft-tissue sarcomas in children account for 6% to 7% of
all childhood malignancies, with rhabdomyosarcomas (RMS)
being the most common, while the others are often referred
to by pediatric oncologists as “sarcomas other than rhabdomyosarcomas” (67–70).
In line with the WHO Soft Tissue Tumors Classification,
four RMS types can be identified: (i) embryonal (ERMS)
including the anaplastic variant; (ii) alveolar with FOXO1
fusions; (iii) spindle/sclerosing RMS including infantile RMS
with VGLL2::NCOA2 rearrangements and RMS with MYOD1
mutations (while those lacking fusions are morphologic variants of ERMS); and (iv) pleomorphic RMS, which is extremely
rare in children and may represent a diagnostic pitfall when
dealing with ERMS with diffuse anaplasia (Supplementary
Table S2). RMS is highly aggressive, but remarkably responsive to conventional chemotherapy with an overall 5-year
survival rate greater than 70% for localized disease (71, 72).
Soft-tissue sarcomas other than RMS account for about
3% to 4% of all pediatric cancers and can be divided into softtissue tumors with intermediate prognosis (locally aggressive
and/or rarely metastasizing), such as infantile fibrosarcoma
or inflammatory myofibroblastic tumor, and high-grade sarcomas, mostly adult-type sarcomas (refs. 73–77; Table 2).
Infantile fibrosarcoma and inflammatory myofibroblastic
tumor are both tyrosine kinase–driven neoplasms and share
similar pathogenetic mechanisms with the emerging category of
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Figure 1. A, Intertumoral heterogeneity of soft-tissue and bone tumors as assessed by DNA methylation array. Unsupervised, nonlinear t-distributed
stochastic neighbor embedding projection of methylation array profiles of 610 soft-tissue and bone tumor samples. Samples have been selected from a large
database of sarcoma datasets to serve as reference profiles for training a supervised classification model based on strict criteria. B–G, Undifferentiated
small round cell sarcomas of bone and soft tissue. B, Ewing sarcoma with EWSR::FLI 1 fusions. C, Soft-tissue sarcoma with BCOR alteration (BCOR::MAML3
fusion). D, CIC::DUX4 sarcoma. CD99 membranous staining varies from strong and diffuse in ES (E) and BCOR::MAML (F) to focal in CIC::DUX4 (G).
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Table 2. Classification of pediatric soft-tissue and bone tumors
Soft-Tissue Tumors
Adipocytic tumors
Lipomatosis
Lipoblastoma/lipoblastomatosis
Liposarcoma
Fibroblastic and myofibroblastic tumors
Fibroblastic and myofibroblastic tumors
Fasciitis
Fibrodysplasia ossificans progressivaa new
Fibroma of tendon sheath
Gardner fibroma
Fibrous hamartoma of Infancy
Lipofibromatosis
Inclusion body infantile digital fibromatosis
Juvenile hyaline fibromatois (Hyaline fibromatosis syndrome)a new
Fibromatosis colli
Calcifying aponeurotic fibroma
Sinonasal angiofibroma
Plantar/palmar fibromatoses
Desmoid fibromatosis
EWSR1::SMAD3 positive fibroblastic tumor
Infantile fibrosarcoma
Pediatric NTRK-rearranged spindle cell neoplasm (provisional entity)b new
Dermatofibrosarcoma protuberans/Giant cell fibroblastoma
Low-grade fibromyxoid sarcoma/Sclerosing epithelioid
Low-grade myofibroblastic sarcoma
Inflammatory myofibroblastic tumor
So-called fibrohistiocytic tumors
Fibrous histiocytoma
Plexiform fibrohistiocytic tumor
Tenosynovial giant cell tumor
Vascular tumors
Capillary malformations
Venous malformations (Venous hemangioma)c new
Arteriovenous malformations (Arteriovenous malformation/hemangioma)c new
Intramuscular vascular anomalies (Intramuscular hemangioma)c new
Lymphatic anomalies (Lymphangioma and lymphangiomatosis)c new
Congenital hemangiomac new
Infantile hemangiomac new
Hemangioma of placenta new
Pyogenic granuloma
Epithelioid Hemangioma
Tufted angioma and kaposiform hemangioendothelioma
Papillary intralymphatic angioendothelioma (PILA) and retiform hemangioendothelioma
Pseudomyogenic hemangiendothelioma
Kaposi sarcoma
Epithelioid hemangioendothelioma
Angiosarcoma
Pericytic (perivascular) tumors
Myofibroma and myopericytoma
Glomus tumor and glomuvenous malformation
Smooth muscle tumors
EBV-associated smooth muscle tumor
Skeletal muscle tumors
Rhabdomyoma
Rhabdomyosarcoma family
Ectomesenchymoma
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Table 2. Classification of pediatric soft-tissue and bone tumors (Continued)
Gastrointestinal stromal tumor
Pediatric gastrointestinal stromal tumor (GIST)
Peripheral nerve sheath tumors
Schwannoma
Neurofibroma
Perineurioma
Hybrid nerve sheath tumor
Granular cell tumor
Solitary circumscribed neuroma
Ectopic meningioma and meningothelial hamartoma
Benign triton tumor/neuromuscular choristoma
Malignant peripheral nerve sheath tumor
Tumors of uncertain differentiation
Tumors of uncertain differentiation
Intramuscular/Juxta-articular myxoma
Superficial angiomyxoma
Deep angiomyxoma
Angiomatoid fibrous histiocytoma
Clear cell sarcoma of soft tissue
Alveolar soft part sarcoma
Extrarenal rhabdoid tumor
PEComa
Synovial sarcoma
Epithelioid sarcoma
Myoepithelial tumors of soft tissue
Phosphaturic mesenchymal tumor
Desmoplastic small round cell tumor
Undifferentiated sarcomas (non-small cell round cells)
Undifferentiated small round cell sarcomas of bone and soft tissue
Undifferentiated small round cell sarcomas of bone and soft tissue
Ewing sarcoma
Round cell sarcoma with EWSR1–non-ETS fusions
CIC-rearranged sarcomas
Sarcoma with BCOR genetic alterations

Bone tumors
Osteogenic tumors
Subungual exostosis
Bizarre parosteal osteochondromatous proliferation
Osteoblastoma
Osteoid osteoma
Chondromesenchymal hamartoma of chest wall
Osteosarcoma
Chondrogenic tumors
Chondroblastoma
Osteochondroma
Chondromyxoid fibroma
Enchondroma and enchondromatosis
Chondrosarcoma
Mesenchymal chondrosarcoma
Other tumors
Vascular tumors of bone
Aneurysmal bone cyst (ABC)
Giant cell tumor of bone (GCTB)
Non-ossifying fibroma (NOF)
Notochordal tumors
Simple bone cyst
(continued)

FEBRUARY 2022

CANCER DISCOVERY | OF9

Downloaded from cancerdiscovery.aacrjournals.org on December 20, 2021. © 2021 American Association for
Cancer Research.

Published OnlineFirst December 17, 2021; DOI: 10.1158/2159-8290.CD-21-1094
Pfister et al.

REVIEW
Table 2. Classification of pediatric soft-tissue and bone tumors (Continued)
Adamantinoma
Osteofibrous dysplasia (OFD)
Fibrous dysplasia
NOTE: Changes with respect to the WHO Classification of Soft Tissue and Bone Tumors 2020 are highlighted in
red (new). Molecularly defined entities are marked in green.
Both these entities are typical pediatric nonneoplastic, tumor-forming diseases; fibrodysplasia ossificans
progressiva was not included in previous WHO soft-tissue tumors editions; for Juvenile hyaline fibromatosis, the
terminology Hyaline fibromatosis syndrome has been added.

a

This provisional entity corresponds to the emerging group of NTRK-rearranged spindle cell neoplasm listed
as “tumors of uncertain differentiation” in the WHO Soft Tissue Tumor Classification 2020, the change in the
name highlights the morphologic relationship with IMT and infantile fibrosarcoma of these lesions in pediatric
patients.

b

The nomenclature used is in agreement with International Society for the Study of Vascular Anomalies classification (55) and reflects the dichotomy between vascular malformation (with specification of vascular type
involved, i.e., venous, arterious or lymphatic or a combination of them) and neoplastic lesions. In parenthesis the
corresponding nomenclature in WHO 2020 Soft Tissue Tumor Classification.

c

“NTRK-rearranged spindle cell neoplasm” (65, 78). This latter
category, currently classified under “tumors with unknown
histogenesis” in the 2020 WHO Classification of Soft Tissue
Tumors, has been redefined as “pediatric NTRK-rearranged
spindle cell neoplasms” and is included in the group of
myofibroblastic tumors in the WHO Pediatric Tumor Classification to highlight their clinicopathologic similarities with
other pediatric myofibroblastic lesions (e.g., lipofibromatosis, infantile fibrosarcoma, and inflammatory myofibroblastic
tumor; ref. 65).
Only the tumor types most frequently occurring in children and adolescents, that is, synovial sarcoma or malignant
peripheral nerve sheath tumors, are described in detail. For
tumor types only rarely occurring in children, a table with a
comprehensive review of reported pediatric cases is provided
in the introduction. Adult-type sarcomas in children may
differ from their adult counterparts in clinical features, morphology, and/or genetic profile. Examples include (i) myxoid
pleomorphic liposarcoma, a liposarcoma type characteristic
of the CAYA age group, that can be associated with Li-Fraumeni
syndrome, and (ii) synovial sarcoma in children showing
minor chromosomal instability (apart from the paradigmatic
SYT::SSX1/SSX2 fusions) compared with its adult counterparts (79). In general, despite the overall aggressive clinical
behavior and low responsiveness to chemotherapy of most
“adult-type sarcomas,” those occurring in children are still
associated with a better prognosis (68, 80, 81).
Bone Sarcomas

Bone sarcomas represent 4% to 8% of pediatric malignancies,
with Ewing sarcomas accounting for about 40% and osteosarcomas for 50% (69). The new section “undifferentiated small
round cell sarcomas” introduced in the 2020 WHO Classification of Soft Tissue and Bone Tumors includes four tumor categories (Fig. 1B–G): Ewing sarcoma, round cell sarcomas with
EWSR1–non-ETS fusions, CIC-rearranged sarcoma, and sarcomas with BCOR genetic alterations. Sarcomas with BCOR alterations are rare, but increasingly recognized by the use of IHC
(BCOR and CCNB3) and molecular tests. While BCOR-internal tandem duplication is typical of infantile undifferentiated
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sarcomas and primitive myxoid mesenchymal tumor of infancy,
BCOR fusions mostly drive the undifferentiated small round
cell sarcomas occurring in adolescents and young adults. By
contrast, CIC-rearranged sarcomas and EWSR1–non ETS fusion
sarcomas are characteristic of adult age.
The differential diagnosis of undifferentiated small round
cell sarcomas requires an integrated approach with different techniques, from the faster and less expensive tests, for
example, FISH or RT-PCR, when a preliminary diagnosis is
suspected based on morphology, to the more sophisticated
and traditionally faster and sometimes even less expensive
NGS panels or RNA-seq. Methylation profiling, which is
widely used in the diagnostic workup of central nervous system (CNS) tumors, also seems to be a promising diagnostic
tool for the classification of soft-tissue sarcomas, especially
for the group of undifferentiated small round cell sarcomas
(Fig. 1A; refs. 11, 82, 83).

Other Solid Tumors
As previously introduced, the WHO Classification of Pediatric Tumors addresses multiple solid tumors by taking a
developmental approach as much as possible, because tumors
in children differ from those in adults at several levels: Children are developing organisms, undergoing multiple and
marked changes at a speed often inversely proportional to the
age of the patient. Congenital and neonatal tumors occur in
immature tissues, where the histologic similarities between
fetal structures and their neoplastic counterparts may not
be immediately obvious (Fig. 2A–F). For example, in peripheral neuroblastic tumors, the most common solid tumor in
children, their histologic appearance is almost indistinguishable from the fetal adrenal medulla (84), which is formed by
migrating neural crest cell precursors that penetrate (one
could say “invade”) the fetal adrenal mesoderm–derived cortex. Indeed, congenital adrenal neuroblastoma “in situ” is
found in between 0.3% and 1% of neonatal autopsies (85).
Details on the classification and molecular makeup of neuroblastoma, including its various clinically relevant molecular
subtypes and associated genetic alterations, are provided in
Supplementary Table S3.
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Figure 2. A–D, Fetal adrenal gland at 21–22 weeks of gestation. A, Migrating neural crest cells penetrate through the mesodermally derived fetal

adrenal cortex homing into the future adrenal medulla (H&E; original magnification 200×). B, SOX10 IHC stain highlights the nuclei of migrating neural
crest cells at the periphery of the migratory clusters, representing future Schwann cell precursors (SOX10 IHC; original magnification 200×). C, Migrating
neural crest cells forming a Homer Wright rosette, indistinguishable from a similar structure in a poorly differentiated neuroblastoma (see E and F).
The Homer Wright rossete is shown in the center, surrounded by fetal adrenal cortex (H&E; original magnification 200×). Inset shows the nonneoplastic
Homer Wright rossete at a higher magnification (400×). Note the fine cytoplasmic prolongations of the future adrenal medullary cells in the center of
the rosette. D, PHOX2B IHC stain showing strong nuclear reactivity in the migrating neural crest cells of the future fetal adrenal medulla (PHOX2B IHC;
original magnification 200×). E and F, Poorly differentiated neuroblastoma from a 1-year-old patient. E, Several Homer Wright rosettes are seen with
their characteristic central area of neuropil (H&E; original magnification 200×). F, PHOX2B IHC stain highlighting the nuclei of the neoplastic neural crest
cells (neuroblasts) in multiple Homer Wright rosettes (PHOX2B IHC; original magnification 200×).

A similar situation occurs with other “blastomas,” which
variably recapitulate the morphologic maturation of cellular
lineages from the organs from which they originate. One of
the best examples is nephroblastoma, also known as Wilms
tumor, which occurs with a frequency close to that of neuroblastic tumors. This neoplasm reproduces the morphologic
steps of renal development to such a high degree that it is
challenging to differentiate a nephrogenic rest from small
Wilms tumors (86, 87). Approximately 10% of Wilms tumors
present histologic changes defined as “anaplasia,” if the following specific criteria are met: nucleomegaly (at least three
times the size of nonanaplastic nuclei), nuclear hyperchromatism, and abnormal/atypical mitoses.
Among some of the innovative approaches in this volume,
the developmental angle used to present the group of germ
cell tumors (GCT) should be highlighted. This group of

heterogeneous neoplasms includes entities that may present
in multiple body locations, affect both sexes, and are particularly frequent in pediatric patients. From the advantageous
position of their shared developmental origins, this chapter
(88) moves along a continuum starting with early embryonic
cells to gradually maturing germ cells. The extensive migratory pathways followed by primordial germ cells (PGC) during embryonic phases, mostly along the midline of the body,
explain their occurrence in seemingly disconnected places
such as the brain, mediastinum, gonads, or sacrococcygeal
areas (88). Therefore, the grouping of GCTs adopts a rendition that considers their origins and progressive maturation
processes responsible for their wide phenotypical varieties
(Table 3). The molecular genetic and epigenetic characteristics
responsible for the progressive maturation process are taken
into consideration for their corresponding classification. The
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Table 3. Classification of pediatric solid tumors
Peripheral neuroblastic tumors
Ganglioneuroma
Ganglioneuroblastoma, intermixed
Neuroblastoma
Ganglioneuroblastoma, nodular (and other composite neuroblastic tumors)

Eye tumors
Conjunctival Neoplasms
Hamartomas
Epibulbar choristoma
Epibulbar osseous choristoma
Phakomatous choristoma
Melanocytic Neoplasms
Conjunctival junctional, compound, and subepithelial nevi
Inflamed juvenile conjunctival nevus
Uveal Neoplasms
Hamartomas
Diffuse choroidal neurofibroma and ganglioneuroma new
Lisch nodule (iris hamartoma)
Retinal and neuroepithelial tumors
Retinocytoma
Retinoblastoma
Medulloepithelioma
Optic nerve tumors
Pilocytic astrocytoma and other gliomas of the optic nerve

Germ cell tumors
Non-invasive germ cell neoplasia
Intratubular germ cell neoplasia (Male gonadal)
Gonadoblastoma
Germinoma family
Germinoma/Dysgerminoma/Seminoma (new as a unifying entity)
Nongerminomatous germ cell tumors
Mature cystic teratoma
Extra-gonadal teratoma
Monodermal teratomas (Female gonadal)
Immature teratoma (Female gonadal)
Prepubertal type testicular teratoma
Post-pubertal type teratoma
Embryonal carcinoma
Yolk sac tumor
Fetus in fetu new
Choriocarcinoma (nongestational)
Malignant mixed germ cell tumors

Renal and male genital tumors
Kidney
Nephroblastic and related tumors
Pediatric cystic nephroma
Nephroblastoma
Molecularly defined renal tumors
Renal cell carcinoma with MIT translocations
ALK driven renal cell carcinoma
Eosinophilic, solid and cystic (ESC) renal cell carcinoma (TSC related)
SMARCB1-deficient renal medullary carcinoma
Metanephric tumors
Metanephric adenoma
Metanephric adenofibroma
Metanephric stromal tumor
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Table 3. Classification of pediatric solid tumors (Continued)
Mesenchymal renal tumors
Ossifiying renal tumor of infancy
Mesoblastic nephroma
Clear cell sarcoma of kidney
Malignant rhabdoid tumor of the kidney
Anaplastic sarcoma of kidney
Renal Ewing sarcoma new
Testis
Juvenile granulosa cell tumor of the testis

Female genital tumors
Ovary
Sex cord-stromal tumors
Ovarian fibroma
Sclerosing stromal tumor
Juvenile granulosa cell tumor of the ovary
Sex cord tumor with annular tubules
Papillary cystadenoma
Sertoli-Leydig tumor
Gynandroblastoma
Other
Small cell carcinoma of ovary, hypercalcemic type
Lower female genital tumors
Epithelial tumors
Mullerian papilloma
Mesonephric remnants and hyperplasia
Condyloma acuminatum
Peritoneum
Mesothelial tumors
Peritoneal inclusion cysts
Breast tumors
Fibroepithelial tumors
Juvenile fibroadenoma
Juvenile papillomatosis

Digestive system tumors
Liver
Epithelial tumors
Hepatoblastoma
Fibrolamellar variant of hepatocellular carcinoma
Pediatric hepatocellular carcinoma new
Mesenchymal tumors unique to liver
Mesenchymal hamartoma
Calcifying nested stromal-epithelial tumor
Embryonal sarcoma of the liver
Hepatic congenital hemangioma new
Hepatic infantile hemangioma new
Hepatic angiosarcoma
Pancreas
Epithelial tumors
Pancreatoblastoma
Pancreatic acinar cell carcinoma
Solid pseudopapillary neoplasm
Gastrointestinal tract
Epithelial tumors
Gastroblastoma
Appendiceal NETs

Endocrine tumors
Thyroid
Thyroid epithelial tumors
Follicular adenoma of the thyroid
(continued)
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Table 3. Classification of pediatric solid tumors (Continued)
Papillary thyroid carcinoma
Medullary thyroid carcinoma
Spindle epithelial tumor with thymus-like elements
Parathyroid
Parathyroid endocrine tumors
Parathyroid adenoma
Adrenal
Adrenocortical tumors
Tumors of the adrenal medulla and extra-adrenal paraganglia
Sympathetic paraganglioma
Parasympathetic paraganglioma (H&N paraganglioma)
Pheochromocytoma
Composite pheochromocytoma/paraganglioma
Neuroendocrine neoplasms

Head and neck tumors
Benign
Squamous cell papilloma of larynx
White sponge nevus new
Congenital granular cell epulis
Central giant cell granuloma
Odontogenic tumors
Ossifying fibroma
Sino-nasal tract myxoma
Nasal dermoid cyst
Nasopharyngeal dermoidNasal chondromesenchymal hamartoma
Pleomorphic adenoma
Malignant
Mucoepidermoid carcinoma
Acinic cell carcinoma
Sialoblastoma
Nasopharyngeal carcinoma
NUT carcinoma
Melanotic neuroectodermal tumor of infancy

Thoracic tumors
Lung
Fetal lung interstitial tumor new
Congenital peribronchial myofibroblastic tumor
Pleuropulmonary blastoma
Heart
Cardiac rhabdomyoma

Skin tumors

Hamartomas new
Epithelial Neoplasms
Squamous
Angiokeratoma
Epidermal nevi (nevus sebaceus) new
Pilomatricoma
Melanocytic neoplasms
Nevi
Congenital neviJunctional, compound, and dermal nevi
Blue nevus and cellular blue nevus
Spitz nevus
Pigmented spindle cell nevus (Reed nevus)
Melanoma
NOTE: Changes respect to the fourth edition of the WHO Classification are highlighted in red (new). Molecularly
defined entities are marked in green.
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critical mechanism appears to be the reprogramming of
nonneoplastic germ cells allowing migrating PGCs to escape
apoptosis, and in later developmental stages, their survival
within gonadal and extragonadal niches (i.e., mediastinum
and brain), from where they can progress to form GCTs in
situ and gonadoblastoma-type lesions, early common origins
of the germinoma family. Reprogramming of lesions in the
germinoma-family line of differentiation may also result in
nonseminomatous tumors. Recognizing gonadoblastoma at
its incipient stages (89) and discriminating it from its mimics
(90) is challenging but important for adequate classification,
treatment, and prognostication.
Pediatric tumors of the digestive system are another area
in which significant progress has been made (91). In this
chapter, several blastomas are presented, including: hepatoblastoma, pancreatoblastoma, and gastroblastoma, which are
unusual neoplasms that require a high level of experience for
their appropriate classification. Molecular pathology information in this chapter has grown exponentially in the last
few years, allowing us to better understand the pathogenesis
of these rare tumors. Regarding the pathology of hepatoblastoma (92), taxonomic efforts are based on the International
Pediatric Tumor Consensus Classification (93), supported
by novel molecular pathology information regarding specific
genetic events relevant for this tumor, especially the WNT/
β-catenin pathway, which is the most important aberrantly
activated signaling pathway in hepatoblastoma (94), although
other genetic abnormalities, such as those involving NFE2L2,
TERT promoter, Notch, Sonic Hedgehog, PI3K/AKT, EGFR,
and the Hippo/YAP pathway are also becoming known players
in the pathogenesis of hepatoblastoma (93–99).
Pancreatoblastoma, which is extremely rare, occurs predominantly in the first decade of life (100, 101) and is also
related to genetic aberrations in the WNT/β-catenin pathway (102–104). Other abnormalities include dysregulation
of IGF2 (105, 106). Pancreatoblastoma may be associated
with Beckwith–Wiedemann syndrome and familial adenomatous polyposis (107, 108). Gastroblastoma is a recently
described tumor (109, 110), arising in the stomach of children and young adults. The tumor shows a recurrent somatic
MALAT1::GLI1 fusion gene (111).
Another chapter included in the pediatric tumor classification covers pediatric skin tumors. To understand pediatric
melanocytic lesions, such as giant congenital melanocytic
naevi (GCMN) and associated disorders, a developmental
approach is again necessary. These are neural crest cell–derived
lesions (112) in which mutations lead to clonal expansion
resulting in congenital melanocytic nevi (CMN). Although
most CMNs harbor NRAS mutations (113), up to 8% of them
carry BRAF mutations (114). Involvement of the CNS (115),
association with neurocutaneous melanocytosis, and malignant transformation to melanoma arising in the context of a
GCMN, although infrequent, represent ominous situations. A
particularly aggressive form of congenital melanoma associated with amplification of mutated NRAS has been reported
(116). Other pediatric skin tumors include hamartomas, epidermal nevi, and additional mosaicism-related abnormalities,
which are frequently difficult to classify morphologically and
are thus presented together with relevant molecular genetic
features (Table 3).

REVIEW
CNS Tumors
The recently published fifth edition of the WHO classification for CNS tumors (summarized in ref. 30) featured a
few fundamental paradigm shifts that particularly affected
pediatric CNS tumor classification and thus formed the basis
for the CNS tumor chapter within the inaugural WHO Classification for Pediatric Tumors. These fundamental changes,
among others, included (i) the general concept of integrating
histologic patterns with state-of-the art molecular diagnostic
readouts to form an integrated diagnosis, (ii) the introduction of designations such as “pediatric-type” and “adult-type”
tumor categories for both low- and high-grade gliomas to
account for the age-specific biology despite the same histology-related names as well as associated cancer-predisposition
syndromes (below), (iii) the inclusion of a multitude of novel
tumor entities, many of which are primarily molecularly
defined (similar to leukemias and lymphomas and some of
the molecularly defined sarcoma types), (iv) the adaptation
of tumor grading as a measure for differential aggressiveness
of tumors within a tumor type rather than between tumor
types, including the suggestion to not report a grade in cases
where this could be clinically confusing because the grade
would not reflect the expected outcome on current treatment regimens (e.g., WNT-driven medulloblastoma CNSWHO grade 4), and (v) the widespread introduction of novel
molecular diagnostic tools such as DNA methylation analysis
for tumor classification, often nominated as an essential diagnostic criterion, particularly for difficult-to-diagnose cases
(ref. 30; Fig. 3).
Tumor entities were selected for more detailed discussion
in the WHO Classification of Pediatric Tumors if they either
mainly occur in children and adolescents, or if a substantial
proportion of an “adult-type” CNS tumor class is diagnosed
in the pediatric age range (summarized in Table 4). All
remaining entities are extensively discussed in the WHO CNS
Tumor Classification.
High-Grade Gliomas

Pediatric-type diffuse high-grade gliomas are now clearly
separated from adult-type diffuse high-grade gliomas (the
latter typically being IDH–wild-type glioblastomas with EGFR
amplification, TERT promoter mutation, and/or combination of gain of chromosome 7 and loss of chromosome 10
or, rarely, high-grade, IDH-mutant astrocytomas or oligodendrogliomas). In the pediatric setting, four different types
are distinguished (Table 4). The designation diffuse midline
glioma, H3K27-altered was widened to include subtypes with
a different mechanism for the loss of H3K27 trimethylation
than H3K27 mutations, for example EZHIP overexpression.
Diffuse midline glioma, EGFR mutant was newly introduced
(Supplementary Table S4).
Infant-type hemispheric glioma was introduced as a new
type, which typically occurs in young children and is associated with receptor tyrosine kinase fusions in the NTRK family,
ROS1, ALK, or MET (117, 118). Diffuse pediatric-type highgrade glioma, H3-wild-type and IDH-wild-type represents a
mixture of quite different molecular subtypes and certainly
needs more granularity, including for instance biologically
distinct subtypes that can readily be distinguished by DNA
methylation analysis (ref. 119; e.g., the methylation classes
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Figure 3. Molecular groups of pediatric CNS tumors (at the level of superfamilies). Unsupervised, nonlinear t-distributed stochastic neighbor embed-

ding (t-SNE) projection of methylation array profiles from 4,427 tumors. Samples were selected from a large database of >90,000 CNS tumor datasets
to serve as reference profiles for training a supervised classification model based on strict criteria: all these samples showed a high calibrated classification score (>0.9) when applying the brain tumor classifier available at https://www.molecularneuropathology.org.

pedHGG MYCN, pedHGG RTK1, pedHGG RTK2, and
HGG_chr6CTX; Fig. 3). They also include tumors with
underlying mismatch repair deficiency (120, 121).
Low-Grade Gliomas

Similar to high-grade pediatric-type gliomas, the designation pediatric-type diffuse low-grade gliomas was introduced
to distinguish these latter (mostly MAPK-driven) tumors
from their adult-type (typically IDH-driven) counterparts.
In contrast to pediatric diffuse low-grade gliomas, in adults
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these tumors generally progress into high-grade gliomas over
the disease course. Several new entities, primarily molecularly
defined, were introduced in this group, including diffuse
astrocytoma, MYB- or MYBL1-altered (122, 123), polymorphous low-grade neuroepithelial tumor of the young (124),
and diffuse low-grade glioma, MAPK pathway–altered (almost
as a diagnosis of exclusion), an exemplary family for which a
mix-and-match approach can be applied by combining a
morphologic diagnosis with a specific genetic alteration, for
example diffuse astrocytoma with FGFR1 mutation (Table 4).
AACRJournals.org
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Table 4. Classification of pediatric CNS tumors
Gliomas, glioneuronal, and neuronal tumors
Pediatric-type diffuse low-grade gliomas
Diffuse astrocytoma, MYB or MYBL1-altered new
Angiocentric glioma
Polymorphous low-grade neuroepithelial tumor of the young new
Diffuse low-grade glioma, MAPK pathway-altered new
Pediatric-type diffuse high-grade gliomas defined by H3 status
Diffuse midline glioma, H3 K27-altered
Diffuse hemispheric glioma, H3 G34-mutant new
Diffuse pediatric-type high-grade glioma, H3-wild-type and IDH-wild-type new
Infant-type hemispheric glioma new
Circumscribed astrocytic gliomas
Pilocytic astrocytoma
High-grade astrocytoma with piloid features new
Pleomorphic xanthoastrocytoma
Subependymal giant cell astrocytoma
Astroblastoma, MN1-altered
Glioneuronal and neuronal tumors
Ganglioglioma
Desmoplastic infantile ganglioglioma/Desmoplastic infantile astrocytoma
Dysembryoplastic neuroepithelial tumor
Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear
clusters (DGONC)a new
Diffuse leptomeningeal glioneuronal tumor
Multinodular and vacuolating neuronal tumor new
Ependymal tumors
Supratentorial ependymoma
Supratentorial ependymoma, ZFTA fusion–positive
Supratentorial ependymoma, YAP1 fusion–positive new
Posterior fossa ependymoma
Posterior fossa ependymoma, Group PFA new
Posterior fossa ependymoma, Group PFB new
Spinal ependymoma, MYCN-amplified new
Myxopapillary ependymoma

Choroid plexus tumors
Choroid plexus papilloma
Atypical choroid plexus papilloma
Choroid plexus carcinoma

CNS embryonal tumors
Medulloblastomas, molecularly defined
Medulloblastoma, WNT-activated
Medulloblastoma, SHH-activated & TP53-wild-type
Medulloblastoma, SHH-activated & TP53-mutant
Medulloblastoma, non-WNT/non-SHH
Medulloblastoma, histologically defined
Medulloblastoma, histologically defined
Other CNS embryonal tumors
Atypical teratoid/rhabdoid tumor
Cribriform neuroepithelial tumora new
Embryonal tumor with multilayered rosettes
CNS neuroblastoma, FOXR2-activated new
CNS tumor with BCOR internal tandem duplication new
CNS embryonal tumor NEC/NOS

Pineal region tumors
Pineoblastoma
(continued)
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Table 4. Classification of pediatric CNS tumors (Continued)
Melanocytic tumors
Meningeal melanocytosis and melanomatosis

Tumors of the sellar region
Pituitary endocrine tumors
Pituitary adenoma/PitNET
Pituitary blastoma new
Craniopharyngiomas
Adamantinomatous craniopharyngioma
NOTE: This table lists CNS tumor types that mainly occur in children and adolescents as well as “adult-type” CNS
tumors of which a substantial proportion is diagnosed in the pediatric age range (*, provisional tumor type for
which additional published studies are needed for full acceptance). Importantly, other “adult-type” CNS tumors
(e.g., spinal ependymoma, meningioma, astrocytoma IDH-mutant) may occur in children as well, those tumors are
extensively discussed in the WHO CNS Tumor Classification. According to WHO terminology, Table 4 distinguishes between categories, families, and types of tumors. For example, the family “Pediatric-type diffuse low-grade
gliomas” represents one of the five families in the overarching category “Gliomas, glioneuronal tumors and
neuronal tumors,” with in this family four tumor types as listed in the table. Of these, diffuse low-grade glioma,
MAPK pathway–altered represents a group of tumors for which a mix-and-match approach can be applied by
combining a morphologic diagnosis with a specific genetic alteration. Also, diffuse pediatric-type high-grade
gliomas, H3-wild-type and IDH-wild-type in fact represent a mixture of quite different molecular subtypes from
which in the future particular members can be expected to emerge as a clinically relevant, more narrowly defined
tumor type (included in current WHO chapter pedHGG MYCN, pedHGG RTK1, pedHGG RTK2; other molecular
subtypes such as HGG_chr6CTX not yet included).
Changes with respect to WHO Classification of CNS Tumors 2016 are highlighted in red (new). Molecularly
defined entities are marked in green.
Provisional entities.

a

Within the category of circumscribed astrocytic gliomas,
high-grade astrocytoma with piloid features was newly
introduced (125) and astroblastoma, MN1-altered more precisely defined (126, 127). Among glioneuronal and neuronal
tumors, diffuse leptomeningeal glioneuronal tumor (128)
and diffuse glioneuronal tumor with oligodendroglioma-like
features and nuclear clusters (24, 25), as a provisional tumor
type, were newly added.
Medulloblastomas

For medulloblastomas, the first layer of classification
remained consistent with the fourth edition update of the
WHO Classification of CNS Tumors in 2016. However,
several aspects have changed: (i) histologic subtypes were
condensed into one type (medulloblastoma, histologically
defined), underscoring that an integrated molecular classification is preferred over a purely histologic classification,
(ii) grading was discouraged for clinical low-risk types
such as WNT-driven medulloblastoma to prevent confusion with treating physicians and patients as explained
above, and (iii) molecular subtypes were introduced for
SHH medulloblastomas (n = 4) and for non-WNT/nonSHH medulloblastomas (n = 8) according to recent publications (129–132). The latter will be of enormous help to
prospectively evaluate the predictive and prognostic role
of these subtypes in the context of state-of-the-art therapies, for example, allowing for therapy deescalation in the
framework of clinical trials for low-risk subtypes other than
WNT. Special emphasis was put on the routine assessment
of the presence of a cancer predisposition syndrome for all
patients with SHH medulloblastoma and CTNNB1–wildtype WNT medulloblastoma (133).
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Ependymomas

The classification of ependymomas has changed from a
mostly morphologic into a primarily molecular classification (Table 4; ref. 12). In the supratentorial compartment,
RELA-driven ependymoma was changed into ZFTA-driven
ependymoma because it appeared that this latter fusion partner is the most consistent one found in this entity (134–136).
YAP1 fusion–driven ependymoma was introduced as a new
type (12). In the infratentorial region, molecularly defined
posterior fossa group A and B (PFA and PFB) ependymomas
were introduced, the first category based on a loss of H3K27
trimethylation in the tumor and/or a methylation profile
indicative of PFA ependymoma (137). In the spinal region,
the recently described type of MYCN-amplified ependymoma
was introduced, a diagnosis associated with particularly unfavorable outcome (138, 139). The difficulty of standardized
grading of ependymoma (especially between grade 2 and
grade 3) was flagged with a caveat, and assigning a CNS WHO
grade is no longer required as part of the diagnosis of ependymomas in children (140).
Other CNS Tumors, Provisional Entities,
and Emerging Entities

Within the category “other embryonal tumors” (Table 4),
molecularly defined CNS neuroblastoma, FOXR2-activated,
and CNS tumor with BCOR internal tandem duplication
were newly introduced. Cribriform neuroepithelial tumor
(CRINET), typically associated with SMARCB1 mutations yet
biologically distinct from atypical teratoid/rhabdoid tumor
(AT/RT), was introduced as a provisional entity (141). The
emerging entity PATZ1 fusion–positive tumor, which was not
included in the CNS tumor classification yet, was, however,
AACRJournals.org
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Li-Fraumeni syndrome*
WILMS TUMOR
• Beckwith-Wiedemann spectrum*
• Bohring-Opitz syndrome
• Mosaic variegated aneuploidy
• Mulibrey nanism
• Perlman syndrome
• Simpson-Golabi Behmel syndrome
• TRIM28 congenital predisposition to WT
• Trisomy 18
• WT1-associated syndromes*
ENDOCRINE TUMORS
• Hereditary pheochromocytoma/
paraganglioma syndrome*
• Hyperparathyroidism jaw tumor
syndrome
• Multiple endocrine neoplasia type 1
• Multiple endocrine neoplasia type 2
• Multiple endocrine neoplasia type 4
• Von Hippel-Lindau syndrome*

HEMATOPOIETIC MALIGNANCIES
• ANKRD26-related thrombocytopenia
and myeloid malignancies*
• Ataxia telangiectasia
• Bloom syndrome
• CEBPA-associated familial AML*
• Congenital neutropenia*
• Down syndrome*
• Dyskeratosis congenita*
• ETV6 susceptibility to ALL*
• Fanconi anemia*
• GATA2-deficiency*
• IKZF1 susceptibility to ALL
• MIRAGE Syndrome*
• Nijmegen breakage syndrome
• Other immunodeficiency syndromes
• PAX5 susceptibility to ALL*
• Ring chromosome 21
• Robertsonian translocation 15;21
• RUNX1 familial platelet disorder with
associated myeloid malignancies*
• SAMD9L ataxia-pancytopenia (ATXPC)
syndrome*
• Shwachman-Diamond syndrome*

REVIEW
Constitutional mismatch repair
deficiency*
GASTROINTESTINAL TUMORS
• APC-associated polyposis syndromes*
• Lynch syndrome*
• MUTYH-associated polyposis
• Peutz-Jeghers syndrome
NEURAL TUMORS
• ALK-related neuroblastic tumor
susceptibility
• Congenital central hypoventilation
syndrome
• ELP1 medulloblastoma syndrome*
• Gorlin syndrome*
• GRP161 medulloblastoma syndrome
• Neurofibromatosis type 1*
• Neurofibromatosis type 2*
• Retinoblastoma predisposition
syndrome*
• Rhabdoid tumor predisposition 1*
• Rhabdoid tumor predisposition 2*
• Schwannomatosis
• Tuberous sclerosis*

OTHERS
• BAP1 tumor predisposition syndrome*
• BRCA1/2-associated hereditary breast
and ovarian cancer syndrome
• Carney complex
• DICER1 syndrome*
• Enchondromatosis
• Hereditary leiomyomatosis and renal
cell cancer
• L-2-hydroxyglutaric aciduria
• Multiple osteochondromas
• NKX2-1 syndrome
• Ornithin transcarbamylase deficiency
• POLE deficiency
• PTEN hamartoma tumor syndrome
• Rasopathies*
• Rubinstein-Taybi syndrome
• Schinze-Giedion syndromel
• Sotos syndrome
• T (Brachyury) gene familial chordoma
• Tyrosinemia Type 1
• Weaver syndrome
• Werner syndrome
• Xeroderma pigmentosum*

Figure 4. Overview on CPSs. For the purpose of this review, syndromes were grouped into eight categories: (1) Li-Fraumeni syndrome; (2) syndromes
predisposing to Wilms tumor; (3) syndromes predisposing to endocrine tumors; (4) syndromes predisposing to hematopoietic malignancies; (5) constitutional mismatch repair deficiency; (6) other syndromes predisposing to gastrointestinal tumors; (7) syndromes predisposing to neural tumors; and (8)
other cancer-prone syndromes. Cancer predisposition syndromes listed in the WHO Classification of Pediatric Tumors and displayed in Suppementary
Table S5 are marked with an asterisk.

mentioned in the introduction to the CNS tumor chapter of
the classification already (142–145). The largest series of these
tumors published to date was published only after the editorial meeting of the WHO (26). In addition, embryonal tumor
with multilayered rosettes (ETMR) was divided into two subtypes: (i) ETMR with C19MC amplification and (ii) ETMR
with DICER1 mutations (often germline; ref. 146). For both
pineoblastoma and AT/RT, the molecular consensus subtypes
were introduced as recently published (147, 148).
In summary, the CNS tumor chapter of the WHO classification for Pediatric Tumors was mostly adopted from the
new CNS tumor classification, which was written at the same
time. This classification will certainly be of enormous value
not only for diagnosticians, but also for treating physicians,
researchers, and patients across the world.

a defined syndrome identified through genome-wide association studies (153, 154). Such low-penetrant cancer risk
alleles are likely to contribute to all childhood cancers. It is
estimated that at least 10% of children with cancer have an
underlying CPS, with the proportion of children with a CPS
being substantially higher for selected cancer types (150).
Estimates in some more recent studies (15, 16, 155) are even
higher; however, this higher incidence might be based on
certain selection biases (e.g., enrichment for relapse patients)
and the stringency of filtering in terms of causality of the
underlying germline mutation. New syndromes continue
to be identified (156, 157). The percentage of underlying
germline genetic variants in cancer predisposition genes varies between populations and may be characterized by founder
mutations, among other factors (158).

Cancer Predisposition

Classification of CPSs

Genetic predisposition is the major known cause of childhood cancer. Research in this area, including integrated
germline and cancer genomic profiling, is highly relevant, as it
provides important biological insights into the causes of childhood cancer and represents a unique opportunity to translate
this knowledge into improving individualized childhood cancer
prevention, surveillance, and treatment in the future.

For the purpose of this review, CPSs are classified into the
following eight different groups (Fig. 4): (i) Li-Fraumeni syndrome (LFS); (ii) constitutional mismatch repair deficiency
(CMMRD); (iii) predisposition to neural tumors, including
neuroblastoma, glioma, medulloblastoma, retinoblastoma,
and rhabdoid tumors; (iv) Wilms tumor predisposition—
these are often overgrowth syndromes (159); (v) endocrine
tumor predisposition; (vi) predisposition to gastrointestinal tumors; (vii) predisposition to hematologic malignancies
including leukemia, lymphoma, and myelodysplastic syndrome (e.g., Fanconi anemia, among others); and (viii) other
CPS (e.g., DICER1 syndrome) not classified within one of the
other groups. Many of the syndromes listed within one main
category predispose to a broader cancer spectrum in and
outside the specific CPS category, while others are associated
with neoplasms in restricted organ systems. The tumor risks
vary substantially between syndromes and genetic subtypes
(e.g., Fanconi anemia; ref. 160). LFS and CMMRD are singled
out because of the particularly high cancer risk and broad

Definition of the Term Cancer Predisposition Syndrome

Cancer predisposition syndromes (CPS) are distinct genetic
or epigenetic conditions associated with an increased cancer
risk compared with the general population. Causes vary and
may include, but are not limited to, constitutional chromosomal anomalies, pathogenic—mainly inactivating but also
activating—variants in single cancer predisposition genes,
copy number changes, and epigenetic mechanisms (149–152).
Several CPSs are characterized by germline mosaicism (151).
Patients with CPS need to be distinguished from individuals harboring cancer risk alleles that are not associated with
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cancer spectrum (161, 162). LFS is also the most commonly
diagnosed CPS among children with cancer (4, 150, 163).
The list of selected CPSs as listed in the WHO Classification
of Pediatric Tumors is provided in Supplementary Table S5.
Adult-Type CPSs

Diagnostic criteria and distinct associated phenotypic characteristics (164) have been established for the most common
CPS; however, with the increasing use of high-throughput
genetic and genomic profiling technologies in the clinical
laboratory, the number of new abnormalities and phenotypic
spectra are evolving including previously unrecognized associations, and patients not meeting diagnostic criteria are being
identified (163). This is particularly true for adult-type CPS.
The increasing use of agnostic germline sequencing has shown
that children with cancer not uncommonly harbor pathogenic/likely pathogenic variants in genes mutated in adult-type
CPS. Examples include heterozygous pathogenic variants in
mismatch repair genes MSH2, MSH6, MLH1, and PMS2 that
typically cause Lynch syndrome and heterozygous pathogenic
variants in BRCA1/2 associated with hereditary breast and
ovarian cancers. While recessive conditions associated with
these genes cause CMMRD and Fanconi anemia, respectively,
and are well established high-risk CPSs in children, it is currently unclear to what extent heterozygous variants in such
genes that also occur at low frequencies in healthy individuals
contribute to cancer risk in children and adolescents. Statistically significant associations have been shown for medulloblastoma (BRCA2, PALB2; ref. 133) and non-Hodgkin lymphoma
(BRCA2; ref. 165). It has also been shown that childhood
cancer survivors who carry variants in DNA repair genes such
as BRCA2 have an increased risk of subsequent neoplasms
(166). Studies analyzing both germline and tumor genomes
(to search for loss of heterozygosity and other characteristic
CPS-specific somatic signatures) are crucial to further clarify
these associations as well as their predictivity for the potential
therapeutic use of PARP inhibitors (16, 18).
Diagnosis of a CPS

Patients with CPS may have clinical features prompting
physicians to suspect and evaluate the diagnosis. These clinical features include individual and family cancer history,
tumor type, presentation (e.g., multifocal, bilateral) as well as
somatic molecular characteristics, and physical features (167,
168). Clinical tools have been developed to identify these
signs systematically (169, 170). However, a significant proportion of CPS is not captured by these tools (171). In addition,
agnostic gene panel or exome-based germline analyses are
increasingly being employed, leading to the identification
of patients with a CPS who lack obvious clinical signs or
symptoms, as well as to the discovery of previously unknown
CPS associations (156, 157, 163, 166).The diagnosis of a CPS
may be challenging due to the notion that variants identified
in a CPS gene may be of uncertain significance, and variant
interpretation challenges should be taken into consideration.
Functional tests such as chromosomal breakage analysis in
patients with Fanconi anemia (172) can help to establish the
diagnosis. Clinical tumor sequencing of pediatric cancers is
also becoming increasingly used, and as a result underlying
cancer predisposition germline variants are often identified
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while sequencing the tumor (173, 174). Pathologists and
geneticists have an important role in recognizing specific
tumor types associated with cancer syndromes and should
actively participate in the multidisciplinary teams evaluating
these patients (175).
Clinical Implications

While it is essential for children with specific cancer types
to be diagnosed or to rule out a specific CPS in order to make
appropriate clinical decisions, ethical aspects need to be
considered and easy access to genetic counseling should be
a requirement for specialized centers diagnosing and treating children with cancer. The diagnosis of a CPS may have
broad clinical implications including identification of other
affected family members through trio or cascade testing, cancer prevention, cancer surveillance, adjusted cancer therapy
to account for resistance to conventional therapy and/or
increased toxicity, and need for psychosocial support (150).
For some patients carrying a pathogenic or likely pathogenic
variant in a CPS gene, direct clinical implications for the
affected child may be less obvious. For example, a heterozygous variant in BRCA1/2 may have no immediate clinical
implications for the affected child with cancer, but it may be
relevant for the patient later in life, and for affected family
members identified through cascade testing. This is because
the cancer risks associated with these variants increase in
adults, warranting specific medical recommendations (e.g.,
breast cancer screening and prophylactic mastectomy).
Summary and Outlook

It is increasingly recognized that childhood cancer has a
strong genetic component. While germline genetic factors are
likely to play a role in all children with cancer, distinct CPSs
(Fig. 4) are currently identified in at least 10% of patients.
Genomic testing, including family-based trio sequencing,
may reveal a new landscape of childhood cancer predisposition. International collaborative studies are needed to
improve treatment strategies, prevention, and surveillance
programs for children with CPS.
The following areas, among others, will need to be further
addressed in the future: (i) discovery of additional germline
(epi)genetic mechanisms contributing to childhood cancer
and corresponding somatic signatures; (ii) cancer epidemiologic studies to better define cancer risks and environmental
as well as (epi)genetic risk modifiers; (iii) improved cancer
surveillance through better imaging and biomarker monitoring; (iv) cancer prevention trials with a focus on high-risk
CPS; (v) interventional treatment studies for patients with
cancer with various CPSs; and (vi) role of digenic, multigenic
mutations as well as the emerging utility of polygenic risk
scores (171, 176, 177).

CONCLUSION
Pediatric tumors represent a particular challenge due to
their rarity, heterogeneity, different pathogenetic mechanisms
compared with adult tumors, strong impact of hereditary
cancer predisposition, and need for therapeutic strategies
that optimize for survival chances while minimizing risks for
long-term sequelae.
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Since the 1970s, international clinical trials have spearheaded a multidisciplinary approach that helped change the
natural history of pediatric leukemias as well as solid and brain
tumors, resulting in a dramatic increase in overall survival and
a better quality of life for the majority of patients. Uniformity
in diagnosis is critical to these efforts. Unfortunately, mortality
rates remain high for advanced diseases and for specific entities, for which survival rates have plateaued for more than two
decades. The integration of classic histologic diagnoses with
advanced molecular techniques such as methylation profiling,
RNA-seq, whole-genome sequencing, or whole-exome sequencing (including tumor and control tissue) represent a step
change in the categorization of pediatric cancers and definition
of prognostic and/or predictive subgroups or biomarkers to be
included in the standard diagnostic process, paving the way
toward more personalized therapeutic strategies.
The inaugural edition of the WHO Classification of Pediatric Tumors provides a basis for a multilayered diagnostic
process that reflects two important aspects:
1. Meeting the needs of regions with varying level of access
to state-of-the art molecular technologies.
2. Acknowledging the current transition from a traditional
system of classification focused on “cell type” to an
integrated approach, also comprising many newly recognized “molecular entities.”
In line with this, the section “essential and desirable diagnostic criteria” included in the fifth WHO edition represents the first basic morphologic diagnostic level, enriched
by a modern, more focused histologic and IHC as well as
broader molecular evaluation (including DNA methylation
and NGS), often derived from the experience in the correlation between molecular patterns and histology (including the
use of artificial intelligence–based approaches). In the future,
this may be further complemented with novel technologies
that add additional information to the tissue analysis, such
as single-cell approaches and proteomics. Noninvasive, NGSbased liquid biopsies to detect circulating tumor DNA seem
a promising tool to plan therapeutic strategies and monitor
tumor evolution, although technical variability is currently
a limiting factor to implementation in routine clinical practice. The integration with information on tumor microenvironment from circulating extracellular vesicles (exosomes)
might, in the future, provide additional important diagnostic/
prognostic data (178).
It is difficult to predict whether molecular platform analyses or even liquid biopsies will fully replace histologic diagnosis on tumor tissue biopsies in the future. However, it is
increasingly clear that molecular techniques are providing a
new, powerful lens to current histologic evaluation, while it
will remain of key importance to actually investigate representative tumor material.
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